Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal International Journal of Health, Engineering and Technology
Ade John Nursalim Nursalim
a:1:{s:5:"en_US";s:31:"RSUP Prof dr R D Kandou, Manado";}
Agriculture, Biological Sciences & Forestry Chemical Engineering, Chemistry & Bioengineering Dentistry Engineering Health Professions Immunology & microbiology Industrial & Manufacturing Engineering Mechanical Engineering Medicine & Pharmacology Nursing Public Health Veterinary

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Evolving Anti-VEGF Therapy For Diabetic Retinopathy: Current Evidence, Durability Strategies, And Future Directions Ade John Nursalim Nursalim
International Journal of Health Engineering and Technology Vol. 5 No. 2 (2026): Vol 5. No. 2 JULY 2026
Publisher : CV. AFDIFAL MAJU BERKAH

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55227/ijhet.v5i2.917

Abstract

Diabetic retinopathy (DR) remains one of the leading causes of vision impairment and blindness among working-age adults worldwide. The introduction of anti-vascular endothelial growth factor (anti-VEGF) therapy has significantly transformed the management of DR by effectively reducing retinal vascular permeability, inhibiting neovascularization, and improving visual outcomes. This article reviews the evolving role of anti-VEGF agents in the treatment of diabetic retinopathy, highlighting current clinical evidence regarding their efficacy, safety, and comparative performance. Particular attention is given to durability strategies designed to reduce treatment burden, including treat-and-extend regimens, high-dose formulations, sustained-release delivery systems, and emerging long-acting therapeutic approaches. The review also discusses the limitations of existing therapies, such as the need for frequent intravitreal injections, patient adherence challenges, and variability in treatment response. Furthermore, future directions are explored, including novel molecular targets, gene-based therapies, combination treatments, and advancements in personalized medicine supported by artificial intelligence and predictive biomarkers. The findings indicate that while anti-VEGF therapy remains the cornerstone of contemporary diabetic retinopathy management, ongoing innovations aimed at enhancing treatment durability and individualized care have the potential to improve long-term outcomes and reduce the global burden of diabetic eye disease.
Co-Authors